Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

• Published in: Blood Vol. 132; no. Supplement 1; p. 790
• Main Authors: Turkina, Anna G, Vinogradova, Olga, Lomaia, Elza, Shatokhina, Evgeniya, Shukhov, Oleg, Chelysheva, Ekaterina, Nemchenko, Irina, Petrova, Anna, Bykova, Anastasiya, Zaritskey, Andrey, Siordia, Nadia, Shikhbabaeva, Dzhariyat, Shuvaev, Vasily, Cortes, Jorge E., Gale, Robert Peter, Baccarani, Michele, Ottmann, Oliver G., Mikhailov, Ilya, Novikov, Fedor, Shulgina, Veronika, Chilov, Ghermes
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 29.11.2018

Background: PF-114 mesylate is a 4th-generation oral tyrosine kinase-inhibitor (TKI) active against wild-type and mutated BCRABL1 isoforms including those with a BCRABL1T315I. We present data from a phase-1 study in subjects with chronic or accelerated phase chronic myeloid leukaemia (CML) failing ≥...